Treatment centers must weigh costs and clinical needs when creating policies for patient drug testing. Meanwhile, investors are examining how drug testing fits in the greater scheme of profits and regulatory risks.
It’s difficult to quantify the prevalence of unethical practices in behavioral health, but most agree it's more a case of criminal enterprise than treatment centers gone bad. See the survey results with expert analysis.
ASAM is accepting public comment on a drug testing appropriateness document that is being developed to provide guidance on drug testing in diagnosis, treatment and promotion of recovery from addiction.
In response to advocacy groups and congressional leaders, the Drug Enforcement Administration halted its attempt to place kratom on the list of Schedule I drugs, however, experts recommend more research on its pharmacology moving forward.
September 13, 2016 | Julie Miller, Editor in Chief
Commercial health insurers paid treatment centers and other providers $445.7 million to treat plan members’ opioid dependence and abuse in 2015, demonstrating a 1,375% spending increase over five years.
As part of a $300 million settlement, UnitedHealthcare will no longer require policyholders to demonstrate abstinence from drugs and alcohol for six months before receiving coverage for a costly hepatitis C medication.